Vivalis SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Valneva SE Wins FDA Market Exclusivity for the Pediatric Indication of IXIARO in the United States
Valneva SE announced that the United States Food and Drug Administration's (FDA) office of Orphan Drug Development (OOPD) granted a seven years orphan drug market exclusivity period for IXIARO for prevention of disease caused by Japanese Encephalitis (JE) virus in children two months to less than 17 years of age. During this seven-year exclusivity period, the FDA will not approve another vaccine for the prevention of JE in children less than 17 years of age, unless such competitive JE vaccine can be shown to be clinically superior to IXIARO in this pediatric population. The seven-year exclusivity period began on May 17, 2013, which coincides with the date of FDA's approval of the pediatric indication for IXIARO.
Latest Developments for Valneva SE
Latest Key Developments in Biotechnology
- Lorus Therapeutics Inc completes $7,001,500 prospectus offering of common shares
- KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
- Zogenix Inc announces FDA approval of four mg SUMAVEL DosePro (sumatriptan injection) needle-free delivery system
- Seattle Genetics Inc highlights ADCETRIS (Brentuximab Vedotin) phase two clinical data in diffuse large B-cell Lymphoma (DLBCL) at ASH 2013
- Share this
- Digg this